新型膀胱癌尿细胞学检测系统的临床应用

Clinical application of a novel urinary cytology detection system for bladder cancer

目的探究新型尿液细胞检测处理试剂盒对于尿液样本的保存作用及新型膀胱癌检测系统对于膀胱癌的诊断效能。方法本研究将初发肉眼血尿患者以及膀胱癌电切术后高危复发患者作为研究对象,自2021年12月-2022年3月前瞻性入组收集患者尿液标本,分别加入(实验组)/不加入(对照组)尿液细胞检测处理试剂盒,于留取样本当天(Day 0)、保存3 d(Day 3)及7 d(Day 7)后分别使用体液细胞学全显染色技术对样本中细胞进行固定、制片、染色、读片,对比两组诊断的敏感性和特异性。结果Day 0实验组敏感性为82.50%(33/40)、特异性为87.50%(14/16),对照组敏感性为79.49%(31/39)、特异性为82.35%(14/17);Day 3实验组敏感性为76.32%(29/38)、特异性为81.25%(13/16),对照组敏感性为52.78%(19/36)、特异性为78.57%(11/14);Day 7实验组敏感性为71.43%(25/35)、特异性为72.22%(13/18),对照组敏感性为35.71%(10/28)、特异性为60.00%(9/15)。Day 3与Day 7实验组敏感性显著优于对照组(P<0.05),其余时间点对照组及实验组的敏感性、特异性无显著差异。结论本膀胱癌尿细胞学检测系统具有明显诊断优势,可作为于膀胱镜检查前的辅助检查手段对血尿患者及膀胱癌复发高危人群进行检查,也可作为膀胱癌筛查手段对大样本人群进行预筛,以实现膀胱癌早诊断、早治疗。

Objective To investigate the diagnostic efficacy of a novel bladder cancer detection system utilizing a urine cell processing kit for urine sample preservation and detection.Methods Patients with primary persistent gross hematuria and high recurrence risk of bladder cancer after transurethral resection of bladder tumor were prospectively enrolled between Dec.2021 and Mar.2022.Urine specimens were either added to(experimental group)or not added to(control group)the urine cell processing kit and were fixed on Day 0,Day 3 and Day 7.The sensitivity and specificity of the two groups were compared after the cells were fixed,produced,stained and read with body fluid cytology total staining technique.Results The sensitivity and specificity of the experimental group on Day 0 were 82.50%(33/40)and 87.50%(14/16),respectively;those of the control group were 79.49%(31/39)and 82.35%(14/17),respectively.On Day 3,the sensitivity and specificity of the experimental group were 76.32%(29/38)and 81.25%(13/16),respectively;those of the control group were 52.78%(19/36)and 78.57%(11/14),respectively.On Day 7,the sensitivity and specificity of the experimental group were 71.43%(25/35)and 72.22%(13/18),respectively;those of the control group were 35.71%(10/28)and 60.00%(9/15),respectively.The sensitivity of the experimental group on Day 3 and Day 7 was significantly higher than that of the control group(P<0.05).Conclusion This bladder cancer urine cytology detection system provides clear diagnostic advantages and can be used as an auxiliary examination before cystoscopy for patients with hematuria and those at high risk of bladder cancer recurrence.It can also be used as a bladder cancer screening tool for pre-screening a large sample of people in order to achieve early diagnosis and treatment of bladder cancer.